glp 1 drug market GLP-1 Drugs Size to Hit USD 132.79 Bn by 2035 The $58B Weight Loss Drug
Description
Back Brown JC, Dryburgh JR, (1971) 'A gastric inhibitory polypeptide II
conversely, Tirzepatide had the slowest onset (19.5 weeks), taking 46 weeks to reach its efficacy plateau
Author Akanksha is a Research Analyst at Verified Market Research, with expertise across Mining, Energy, Chemicals, and Transportation markets
Market performance has also benefited from growing physician acceptance, favorable clinical evidence, and improved patient adherence due to enhanced delivery systems
